Get access

Reducing the financial impact of pathogen inactivation technology for platelet components: our experience

Authors

  • Enrique Girona-Llobera,

    1. Fundació Banc de Sang i Teixits de les Illes Balears, Majorca, Spain
    2. Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Majorca, Spain
    3. Son Espases University Hospital, Majorca, Spain
    Search for more papers by this author
    • These authors contributed equally to this work.
  • Teresa Jimenez-Marco,

    Corresponding author
    1. Fundació Banc de Sang i Teixits de les Illes Balears, Majorca, Spain
    2. Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Majorca, Spain
    3. Son Espases University Hospital, Majorca, Spain
    • Address reprint requests to: Teresa Jimenez-Marco, Fundació Banc de Sang i Teixits de les Illes Balears, C/Rosselló i Caçador, 20, 07004, Palma de Mallorca, Balearic Islands, Spain; e-mail: matejimenez@hotmail.com; tjimenez@fbstib.org.

    Search for more papers by this author
    • These authors contributed equally to this work.
  • Ana Galmes-Trueba,

    1. Fundació Banc de Sang i Teixits de les Illes Balears, Majorca, Spain
    2. Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Majorca, Spain
    3. Son Espases University Hospital, Majorca, Spain
    Search for more papers by this author
  • Josep Muncunill,

    1. Fundació Banc de Sang i Teixits de les Illes Balears, Majorca, Spain
    2. Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Majorca, Spain
    3. Son Espases University Hospital, Majorca, Spain
    Search for more papers by this author
  • Carmen Serret,

    1. Fundació Banc de Sang i Teixits de les Illes Balears, Majorca, Spain
    2. Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Majorca, Spain
    3. Son Espases University Hospital, Majorca, Spain
    Search for more papers by this author
  • Neus Serra,

    1. Fundació Banc de Sang i Teixits de les Illes Balears, Majorca, Spain
    2. Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Majorca, Spain
    3. Son Espases University Hospital, Majorca, Spain
    Search for more papers by this author
  • Matilde Sedeño

    1. Fundació Banc de Sang i Teixits de les Illes Balears, Majorca, Spain
    2. Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Majorca, Spain
    3. Son Espases University Hospital, Majorca, Spain
    Search for more papers by this author

Abstract

Background

Pathogen inactivation (PI) technology for blood components enhances blood safety by inactivating viruses, bacteria, parasites, and white blood cells. Additionally, PI for platelet (PLT) components has the potential to extend PLT storage time from 5 to 7 days.

Study Design and Methods

A retrospective analysis was conducted into the percentage of outdated PLT components during the 3 years before and after the adoption of PLT PI technology in our institution. The PLT transfusion dose for both pre-PI and post-PI periods was similar. A retrospective analysis to study clinical safety and component utilization was also performed in the Balearic Islands University Hospital.

Results

As a result of PI implementation in our institution, the PLT production cost increased by 85.5%. However, due to the extension of PLT storage time, the percentage of outdated PLT units substantially decreased (−83.9%) and, consequently, the cost associated with outdated units (−69.8%). This decrease represented a 13.7% reduction of the initial cost increase which, together with the saving in blood transportation (0.1%), led to a saving of 13.8% over the initial cost. Therefore, the initial 85.5% increase in the cost of PLT production was markedly reduced to 71.7%. The mean number of PLT concentrates per patient was similar during both periods.

Conclusions

The extension of PLT storage time can substantially contribute to reducing the financial impact of PI by decreasing the percentage of outdated PLTs while improving blood safety. Since the adoption of PI, there have been no documented cases of PLT transfusion–related sepsis in our region.

Ancillary